NEPG(SZ:000597)2021-10-25 16:00Financial Performance - The company's operating revenue for Q3 2021 was ¥2,095,508,856.12, representing an increase of 18.83% compared to the same period last year[6]. - The net profit attributable to shareholders of the listed company was -¥34,886,461.37, a decrease of 39.22% year-on-year[6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥37,411,451.65, which is a decrease of 59.03% compared to the previous year[6]. - Total operating revenue for the third quarter reached ¥6,105,215,984.83, an increase of 11.25% compared to ¥5,486,780,804.00 in the same period last year[31]. - Net profit for the quarter was ¥28,872,569.34, significantly higher than ¥4,443,961.92 in the previous year, marking a substantial increase[33]. - The net profit attributable to the parent company was CNY 25,497,646.56, compared to CNY 811,899.43 in the previous period, indicating significant growth[38]. - The total comprehensive income attributable to the parent company was CNY 25,386,350.67, up from CNY 331,044.28 in the previous period[38]. - Basic and diluted earnings per share were both CNY 0.0189, significantly higher than CNY 0.0006 in the previous period[38]. Assets and Liabilities - Total assets at the end of the reporting period were ¥13,890,768,511.33, an increase of 14.18% from the end of the previous year[6]. - As of September 30, 2021, the company's total current assets amount to 7,446,345,470.08 RMB, an increase from 5,553,150,795.57 RMB at the end of 2020[22]. - The company's total assets increased to ¥13,890,768,511.33 from ¥12,165,694,782.80, representing a growth of 14.16%[29]. - Total liabilities rose to ¥9,636,609,547.09, compared to ¥8,043,488,704.77, indicating an increase of 19.77%[29]. - Total current liabilities were approximately CNY 7.32 billion[51]. - Total liabilities amounted to approximately CNY 8.04 billion[51]. - The company’s total liabilities increased by approximately 0.96% compared to the previous period[51]. Cash Flow - The company's cash flow from operating activities was ¥440,218,469.84, showing a decrease of 4.88% year-to-date[6]. - The net cash flow from operating activities was CNY 440,218,469.84, slightly down from CNY 462,788,965.54 in the previous period[41]. - The net cash flow from investing activities was -CNY 580,488,137.61, worsening from -CNY 294,628,653.28 in the previous period[44]. - The net cash flow from financing activities was CNY 454,196,622.11, compared to CNY 274,316,603.83 in the previous period, showing improvement[44]. - The company received CNY 3,170,304,000.00 in cash from borrowings, compared to CNY 3,131,000,000.00 in the previous period, indicating stable financing activities[44]. - The company paid CNY 2,417,600,000.00 in cash for debt repayment, down from CNY 3,092,600,000.00 in the previous period, reflecting improved cash management[44]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 34,897[13]. - The largest shareholder, Liaoning Fangda Group, holds 24.41% of shares, totaling 329,068,713 shares[13]. - After the transfer agreement, Fangda Steel holds 188,366,359 shares, representing 13.98% of the total share capital[19]. - The company completed the transfer of 254,865,083 shares to Fangda Steel, which triggered a mandatory tender offer[18]. - The total price for the share transfer was 1,251,387,557.53 RMB[18]. - Fangda Steel became the largest shareholder with 32.88% of the total share capital after the completion of the share transfer[21]. Market Challenges - The company faced challenges in market sales due to the impact of the COVID-19 pandemic, which significantly affected the demand for pharmaceutical products[8]. Research and Development - Research and development expenses for the quarter were ¥34,009,934.42, a decrease from ¥45,763,763.14 in the previous year, showing a reduction of 25.7%[33].